Netherlands Oncology Clinical Trials Market Analysis

Netherlands Oncology Clinical Trials Market Executive Summary

Netherlands oncology clinical trials Market is projected to grow from $32.9 Mn in 2022 to $52.4 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The most prevalent malignancies among women in the Netherlands are lung, colon, and breast cancer. In 2022, 124.109 people were diagnosed with cancer: 65.591 males and 58.518 women. In the Netherlands, more than 850.000 people have cancer or have survived cancer. The Netherlands was one of the first nations to establish a cancer institute: the Netherlands Cancer Institute (NKI). The NKI, which was founded in 1913, is today one of the world's greatest comprehensive cancer centers.

Many oncology clinical trials are now underway in the Netherlands. These studies are intended to put innovative cancer treatments, therapies, and diagnostic technologies to the test. These studies are taking place in many medical facilities and hospitals around the Netherlands, including the Erasmus Medical Center, the University Medical Center Utrecht, and the Netherlands Cancer Institute. The Netherlands has a well-developed healthcare system and a solid research infrastructure, making it a suitable site for clinical trials. The nation also boasts a highly educated populace, with many people eager to take part in clinical trials to enhance medical knowledge and improve cancer treatment choices.

Market Dynamics

Market Growth Drivers

Oncode Institute, one of the biggest strategic public-private collaborations in the Netherlands, brings together 800+ exceptional cancer researchers from 12 universities, academic hospitals, and research organizations. The Netherlands is leading in oncology not only in Europe, but across the globe, owing to innovative prevention, diagnostics, and therapies nurtured in a connected and collaborative environment. According to recent research, the Netherlands is the second-best country in the world for cancer treatment and the best in Europe. With over 500 public-private collaborations, a key location for R&D cooperation, and accessibility for Europeans seeking treatment – as well as solid logistics to simplify manufacture and distribution worldwide - the country is well-positioned. The country's strong healthcare system experienced clinical researchers, and the supportive government provides a solid foundation for growth in this area.

Market Restraints

There are certain limitations to oncology clinical trials in the Netherlands. One of the most significant challenges is the stringent standards regulating clinical studies. The regulatory procedure may be time-consuming and complicated, and failing to comply can result in fines. This may be difficult for certain firms, especially those unfamiliar with the Dutch regulatory structure. Competition is another challenge confronting oncology clinical trials in the Netherlands. Since nations compete to recruit clinical trials, the Netherlands may face competition from other countries that provide comparable benefits. Additionally, although the Netherlands government funds research and development, financing for clinical trials may be difficult to come by. Many organisations need substantial financial resources to perform clinical trials, and obtaining financing may be difficult.

Competitive Landscape

Key Players

• Roche Holding AG
• Pfizer Inc.
• Novartis International AG
• Merck & Co., Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Sanofi S.A.
• Bristol Myers Squibb Company
• Kiadis Pharma (NLD)
• ISA Pharmaceuticals BV (NLD)

Notable Insights

1. February 2023, The Netherlands Cancer Institute is doing research on a novel form of mesothelioma therapy. For individuals with BAP1 genetic alterations, researchers are investigating a unique combination of current drugs.
2. September 2022, the new treatment, according to the researchers at the Netherlands Cancer Institute, utilizes a patient's own immune cells to attack cancer, and its therapy is comparable to another form of treatment that has shown to be very successful for blood malignancies, known as CAR-T therapy.
3. April 2022, The Netherlands is investing 325 million euros ($351 million) in the development of preclinical cancer drugs. The Netherlands National Growth Fund intended to use the funds to establish specific competencies that would aid biotech in the development of cancer prospects.

Healthcare Policies and Regulatory Landscape

The Netherlands maintains two registries related to clinical trials. The Central Committee on Research Involving Human Subjects (CCMO) is a national registry that requires clinical trial data performed in the Netherlands or by a Dutch researcher to be posted. The summary findings must be submitted to the CCMO registry. Another registry that allows protocol registration is the National Trial Registry (NTR). It is a main registry recognized by the World Health Organization (WHO). NTR will have a new website starting on December 15, 2022. The NTR is administered by the CCMO, and once fully operational, the CCMO will reapply to the WHO for registration recognition.

The European Union Clinical Trial Information System (EU CTIS) became operational on January 31, 2022, and the Clinical Trials Regulation (Regulation (EU) No 536/2014) is currently in effect. EU CTIS will assist with protocol registration as well as results reporting for clinical trials performed in the EU/EEA.